Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.

 Lorcaserin hydrochloride hemihydrate

Product name: lorcaserin hydrochloride hemihydrate
other names: (1r)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1h-3-benzazepine hydrochloride hemihydrate;lorcaserin hydrochloride hemihydrate;lorcaserin hcl 0.5h2o;(r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine dihydrochloride hydrate;(r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine hydrochloride hydrate(2:2:1);r-lorcaserin hydrochloride hemehydrate;lorcaserin hcl hemihydrate;belviq
cas no.: 856681-05-5
molecular formula: 2(c11h14cln).2(hcl).h2o
appearance: white or nearly white crystalline powder
purity: 99%+
suitable people: all people
product specifications: pharmaceutical grade 
standard: Company standard
moq(minimum order quantity): 25g

applications/usage:

Lorcaserin(856681-05-5) is appetite depressant.agent that is used to decrease appetite.

      Obesity has become a worldwide problem since the extra weight can increase the risk of hypertension, diabetes, hyperlipidemia, stroke, heart disease, and osteoarthritis. Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.